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Background: Previous studies in our laboratory demonstrated that a synthetic peptide containing 
lung surfactant enhances the permeability of chemical compounds through bronchial epithelium. 
The purpose of this study was to test two formulations of Synsurf® combined with linezolid as 
respirable compounds using a pressurized metered dose inhaler (pMDI).
Methods: Aerosolization efficiency of the surfactant-drug microparticles onto Calu-3 monolay-
ers as an air interface culture was analyzed using a Next Generation Impactor™.
Results: The delivered particles and drug dose showed a high dependency from the preparation 
that was aerosolized. Scanning electron microscopy imaging allowed for visualization of the 
deposited particles, establishing them as liposomal-type structures (diameter 500 nm to 2 µm) 
with filamentous features.
Conclusion: The different surfactant drug combinations allow for an evaluation of the signifi-
cance of the experimental model system, as well as assessment of the formulations providing 
a possible noninvasive, site-specific, delivery model via pMDI.
Keywords: Calu-3, pMDI, linezolid, delivery vehicle, pulmonary surfactant, aerosolized particles
Introduction
Considerable effort has been invested in generating aerosols for pulmonary delivery 
over the last 10 years. In this regard, administering clinically relevant dosages of inhaled 
drug and control of lung-regional distribution thereof has proven to be challenging. The 
principle aim of inhalation of drugs for pulmonary disease therapy is to increase the 
local drug concentration and avoid systemic toxicity of the said compounds.1 However, 
lung is a complex organ that is regulated by multiple factors such as the structure of 
the epithelia, the physicochemical properties of the drug as well as the type of delivery 
system used. Although improved drug deposition remains an important aim, enhanced 
therapeutic effects does not necessarily follow. Studies of drug deposition and transport 
in vitro may reveal the fate of deposited particles on respiratory epithelia, which 
may allow for better understanding of similar happenings in vivo.2 Human bronchial 
adenocarcinoma, Calu-3 cell line, due to its simple reproducible process and similarity 
to in vivo physiology, has become the alternative investigatory model for the in vitro 
study of proximal airway respiratory exposure to better understand the determinants 
that influences pulmonary drug dissolution, absorption, metabolism, and efficacy.3,4
Aerosolized antibiotic formulations and novel delivery systems for the treatment 
of cystic fibrosis, pneumocystis pneumonia, or pulmonary tuberculosis may over-
come the time burden of therapy and improve clinical outcomes due to increased 
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patient complience.5 Furthermore, pMDIs provide patients 
with a versatile, reliable, instantly available, self-contained, 
portable, low-cost medical aerosol delivery system.6 The 
encapsulation of antibiotics in liposomes is another novel 
concept regarding aerosolized drug delivery as revealed by 
Meers et al.7 They demonstrated the targeted pulmonary 
delivery of amikacin via liposomal encapsulation-enhanced 
antibiotic penetration of mucus and biofilm on the surface 
of the epithelium.7 Although various drugs have been tested 
in combination with lipid particles, the synthetic lung sur-
factant Alveofact® was the first liposomal product to reach 
the market in 15–20 years.8
From a drug delivery perspective, the objective of this 
study was to investigate whether the use of two formulations 
of the pulmonary surfactant Synsurf®, combined with linezolid, 
is suitable as carrier, drug delivery, and permeation agent for 
inhalation. Although the idea to use lung surfactant as a carrier 
agent was proposed several years ago with a tobramycin–
surfactant mixture, we have shown in our previous studies 
that Synsurf enhances the permeability of drugs such as 17β-
estradiol, hydrocortisone, dexamethasone, zidovudine, and 
isoniazid across porcine bronchial tissue.9 This new synthetic 
pulmonary surfactant contains the amphipathic phospholipid 
dipalmitoylphosphatidylcholine (DPPC), surface-active phos-
phatidylglycerol, as well as 1-hexadecanol, tyloxapol, and a 
polymer peptide complex of poly-l-lysine and poly-l-glutamic 
acid. It is an entirely synthetic pulmonary surfactant containing 
peptides that mimic the action of naturally occurring surfactant 
proteins SP-B/C and avoids the potential risk of animal-derived 
pathogen transmission.10 Its efficacy proved to be similar to that 
of the commercially available naturally derived surfactants, 
that is, Curosurf®, in a preterm lamb model.11 
The aim of this study was therefore to test linezolid 
combined with Synsurf in a pressurized metered dose inhaler 
(pMDI) by using a Calu-3 cell line as target model. To our 
knowledge, this is an unexplored area with the drug. 
Materials and methods
reagents and standards
High-performance liquid chromatography (HPLC) grade 
acetonitrile (Romil, Cambridge, UK), MilliQ water (EMD 
Millipore, Billerica, MA, USA), and ammonium acetate (Ana-
lytical; EMD Millipore, Billerica, MA, USA) were used in the 
mobile phase. The rest of the analyte standards and linezolid 
were supplied by Sigma-Aldrich Co. (St Louis, MO, USA). 
culture of calu-3 cells
The Calu-3 cell line (ATCC® HTB-55™) (passage 33–36) 
was first cultured as a polarized liquid-covered culture in 
75 cm2 flasks and maintained in a humidified, 5% CO
2
, 
95% atmospheric air incubator at 37°C before subcultured 
in 12 cm diameter Corning® Costar® Transwell® inserts 
(0.33 cm2 polyester, 0.4 µm pore size) from Sigma-Aldrich 
Co. The culture medium was composed of Dulbecco’s 
Modified Eagle’s Medium supplemented with 10% fetal 
calf serum, 1% nonessential amino acid solution (×100), 
1% l-glutamine solution (200 mM), and 1% penicillin-
streptomycin.
Cells cultured on Transwell supports were seeded at 
a density of 5×105 cells/cm2 and were introduced into the 
apical surface of the Transwell support in 0.2 mL medium 
with 2 mL medium added to the basolateral chamber. The 
cells were incubated at 37°C, 5% CO
2
 for 24 hours. For air–
liquid interface (ALI) culture, the cell culture medium was 
removed on day 2 post-seeding. The cell layers were evalu-
ated through light microscopy with a Nikon TMS Inverted 
Phase Contrast Microscope (Nikon Corporation, Tokyo, 
Japan). Trans-epithelial electrical resistance (TEER) was 
measured using an EVOM2 chopstick electrode and EVOM2 
Epithelial Volt/Ohm meter (World Precision Instruments, 
Sarasota, FL, USA). TEER can only be measured through 
liquid; therefore, pre-warmed medium (0.2 mL, 37°C) was 
added to the apical chambers and returned to the incubator 
to equilibrate for a further 30 min before evaluation as to 
avoid any disturbed epithelial electrical resistance readings. 
TEER was calculated by subtracting the resistance of a cell-
free culture insert with correction for the surface area of the 
Transwell cell culture support. When the TEER had reached 
a value of .700 Ω cm2 in submersed culture, it was consid-
ered confluent. In ALI culture, the medium (1.5 mL) in the 
basolateral compartment was changed every 2–3 days. 0.2 
and 1.5 mL media were added to the apical and the basolateral 
compartment, respectively, for TEER measurements.
TEER values were calculated as follows:
 
TEER R R A
Sample blank
= − ×( )
 
where R
Sample
 is the experimental value of cells, R
blank
 is the 
experimental value of the blank control which is defined as 
the resistance of the membrane without cells, and A is the 
surface area of the filter membrane (1.12 cm2). TEER was 
expressed in Ω cm2.12
cell surface staining
Alcian blue staining was employed for the detection of gly-
coproteins at day 1, day 7, and day 14 post seeding at ALI. 
Cell layers were washed twice with 100 mL Hanks’ balanced 
salt solution (HBSS) and fixed for 10 min by using 2.5% (v/v) 
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glutaraldehyde in 0.1 M sodium cacodylate buffer. The cells 
were washed again with HBSS and 100 mL alcian blue stain 
(1% [w/v] alcian blue in 3% [v/v] acetic acid/water at pH 2.5) 
was added for 1 hour. The dye was then removed and the cell 
layer washed with HBSS until the rinsate ran clear (images 
not included).
surfactant preparations
Two synthetic surfactant preparations were used in the 
study: 1) Synsurf prepared as described previously by van Zyl 
et al13 (prep 1) and 2) Synsurf formulated with the addition 
of 2 wt% cholesterol (prep 2). Both the formulations were 
then freeze-dried for further use in the pMDI.
synsurf® pMDis
Canisters were filled with a 1:1 ratio of linezolid to Synsurf 
(prep 1 and 2) to yield a final concentration of 200 µg. Hydro-
fluoroalkane propellant (Mexichem-Fluor, Runcorn, UK) was 
added, and the canisters were sealed with a Pamasol Manual 
Crimper and Filler (DH Industries, Essex, UK). Three canis-
ters were conveyed as: L = linezolid alone, LP1 = linezolid + 
Synsurf prep 1, and LP2 = linezolid + Synsurf prep 2. A total 
of five actuations were studied per experiment.
scanning electron microscopy (seM), 
cell surface morphology, and pMDi 
drug deposition
The fixative solution, 2.5% glutaraldehyde and 0.5 g potas-
sium ferrocyanide dissolved in 50 mL of normal strength 
culture media (without serum), was added to the basolateral 
chambers of the Transwell plates post pMDI actuation. The 
fixative was not added to the apical layer as to avoid possible 
“emulsion” of surfactant and/or linezolid. Rather, the plates 
were covered within a glass dome with fixative solution in 
neighboring wells for 2 hours allowing the apical side to be 
fixed via gaseous means. Cells were then washed with serum-
free media and post-fixed with 1% osmium tetroxide + 1% 
potassium ferrocyanide for 1 hour at room temperature on the 
apical and basolateral sides. Cells were washed twice with 
distilled water over 15 min. The membranes were carefully 
cut out of the Transwell inserts and placed in small glass 
vials and stained with 2% aqueous uranyl acetate for 1 hour 
in the dark. Membranes were further washed with acetone 
50%, 70%, and 90% each once over 10 min and then twice 
with 100% acetone, followed by one 15-minute wash with an 
equal mix of acetone and hexamethyldisilazane (HMDS) and 
then two final 15-minute washes with HMDS. Acetone was 
chosen as a preferable dehydrating agent as it may cause less 
shrinkage of the samples than ethanol, and it is not reactive 
with any 0s0
4
 that may remain in the samples. HMDS was 
used as a chemical alternative to critical point drying (CPD) 
method due to its ease of use, relative quickness, and afford-
ability. It also dehydrates without compromising the under-
lying structures and avoids the turbulence created by CPD 
when considering gentle structures.14
Membranes were left partially covered overnight and 
subsequently sputter coated with gold to achieve a thickness 
of ~20 nm (Edwards Sputter Coater S150B; Edwards High 
Vacuum, Sussex, UK). Imaging was performed using a SEM 
(JOEL SEM6480LV system, Tokyo, Japan). 
in vitro aerosol deposition studies using 
a next generation impactor (ngi) device 
and dissolution analysis
A multistage cascade Next Generation Impactor™ (NGI™; 
Copley Scientific, Nottingham, UK) was used for testing 
metered-dose inhalers. The impaction plates of the NGI were 
modified to accommodate six Transwells at three stages. This 
allowed the study of different particle size fractions. The 
loaded device was connected to the throat (induction port) 
of the NGI via a molded silicone mouthpiece. Testing was 
performed at 60 L/min flow rate with a 5-second exposure 
after each actuation. A dissolution assay of samples in the 
basolateral Transwell was performed upon each actuation 
(n=2). Samples were vortexed for 30 seconds with HBSS 
buffer (Sigma-Aldrich Co.), containing HEPES (10 mM) and 
a 0.025% Tween and then centrifuged for 10 min at 3,000 
rpm. Supernatants (±1 mL) were then transferred to HPLC 
vials. At the end of the experiment, the surface of the Calu-3 
cells were washed with buffer and collected for the analysis of 
residual apical drug. This allowed for the calculation of total 
drug deposited via the cumulative sum of all samples.
analyses of linezolid by liquid 
chromatography–mass spectrometry 
(lc-Ms) 
A Waters Synapt G2 quadrupole time-of-flight mass spec-
trometer (Waters Corporation, Milford, MA, USA), fitted with 
a Waters Acquity UPLC and photo diode array (PDA) detec-
tor was used for LC-MS analyses. Separation was achieved 
on a Waters BEH Amide UPLC column (2.1×100 mm, 
1.7 µm) at a temperature of 35°C. Solvent A consisted of 
10 mM ammonium acetate in water, solvent B consisted of 
10 mM ammonium acetate in 95% acetonitrile. The gradient 
consisted of a flow rate 0.25 mL/min, starting with 95% B 
to 40% B over 9 min, applying gradient curve over 7 min, 
followed by re-equilibration to initial conditions over 5 min. 
Electrospray ionization was applied in the negative mode, 
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using a capillary voltage of 2.5 kV, a cone voltage of 15 V, 
desolvation temperature of 250°C and desolvation gas (N2) 
flow of 650 L/h. The rest of the MS settings were optimized 
for best sensitivity. Data were acquired in MSE mode, 
consisting of a scan using a low collision energy and a scan 
using a collision energy ramp from 25 to 60 V, which has 
the added advantage of acquiring low energy molecular ion 
data as well as fragmentation data for all analytes over time. 
Data were collected using a scan rate of 0.2 seconds over 
the range m/z 100–1,000. Leucine enkaphalin was used as 
lock mass for accurate mass determination on the fly with a 
lock mass flow rate of 0.002 mL/min, acquiring lock mass 
data every 20 seconds. Sodium formate was used to calibrate 
the instrument. The PDA detector was set to scan over the 
range 220–450 nm.
Drug permeability
The transport of compounds across Calu-3 cells is typically 
expressed in terms of the apparent permeability coef-
ficient (P
app
) measured in the absorptive apical to baso-
lateral (Ap-Bl) direction and was calculated according to 
Equation 1: 
 
P
dQ
dt A Capp
= ×
×
1
0  
(1)
where dQ/dt is the linear transport rate of the compound, 
A is the surface area of the cell layer, and C
0
 is the initial 
compound concentration in the donor chamber.
surface tension and interfacial rheology 
experiments
Surface tension behavior of four different preparations, 
namely Synsurf, Synsurf + linezolid (prep 1), Synsurf + cho-
lesterol, and Synsurf + cholesterol + linezolid (prep 2), was 
systematically examined using pendant and pulsating drop 
configurations at the ALI. Sample concentration of test prepa-
rations was as follows: Synsurf 90 µg, cholesterol 2% by 
weight, linezolid 90 µg. A computer controlled One Attension 
Theta Optical Tensiometer (Biolin Scientific, Manchester, 
UK) was used for these experiments. A 15 µL droplet of each 
preparation was tested at 25°C for its surface tension lowering 
effect over 60 seconds with the pendant drop module of the 
instrument. Sequential data images of the suspended droplet 
were collected by the camera at a rate of one image per 
second (~2,000 data points). For each preparation, five drops 
were tested. Dilatational visco-elastic properties of Synsurf 
preparations were analyzed at 37°C. A 15 µL surfactant 
bubble was subjected to oscillation frequencies between 
0.25 and 6 Hz (sine waveform; 10 oscillations/frequency; 
amplitude 1). Experiments done are representative of seven 
repeats for each preparation.
statistical analysis
All the results are expressed as mean ± standard deviation 
of at least two replicate experiments. Data were analyzed 
by GraphPad Prism, Version 5, statistical software package 
(GraphPad Software, Inc., La Jolla, CA, USA). One-way 
analysis of variance (ANOVA, with Tukey’s post hoc 
analysis) was used to test for significance between the treat-
ment groups. The confidence interval (CI) of 95% was also 
calculated based on the mean, and significant difference was 
accepted at P-values of #0.05. 
Results
Transepithelial resistance
Calu-3 cells were grown at the air interface to allow mono-
layer differentiation, and experiments were performed 
between days 11 and 14 when TEER reached values between 
750 and 1,000 Ω cm2. These conditions have previously 
been established by Haghi et al.15 After the high TEER was 
determined and thus the presence of tight junction proteins 
was confirmed, the surface properties of Calu-3 cells were 
studied by SEM pre- and post-pMDI impactor actuation.
Transepithelial drug transport
The average particle size (D
50
) for the NGI stages was estab-
lished as follows: stage 2: 4.46 µm; stage 3: 2.82 µm; and 
stage 4: 1.66 µm at a flow rate of 60 L/min.16 Uptake and 
transport experiments with linezolid were performed 14 days 
after seeding and trans-epithelial flux measurements were 
performed as well as total trans-epithelial drug transported 
and cellular uptake were calculated. 
Apparent permeability for the three separate preparations 
in the absorptive direction (apical-to-basal) were determined 
for 240 min (after a 20-minute preincubation to establish a 
state of linear flux). Fluxes are expressed as ng/mm2/min. 
The passive (paracellular) route across the epithelium was 
estimated by repeated linezolid flux determinations that 
indicated steady-state diffusion. 
Since these parameters are difficult to control, that is, the 
amount of recovered sample (start concentration in apical 
compartment, volume and the amount of samples within each 
NGI chamber), the initial compound concentration (C
0
) in 
the donor chamber was established at the end of each uptake 
experiment (4 hours). The total amount of linezolid collected 
 
D
ru
g 
De
sig
n,
 D
ev
el
op
m
en
t a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
6.
23
2.
12
5.
2 
on
 1
6-
Se
p-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Drug Design, Development and Therapy 2018:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1111
linezolid pMDi: a calu-3 model
from the basal compartment and the drug remaining on the 
cell surface and inside the cells were summed to represent 
total deposited mass.17
Figure 1 displays the total drug masses deposited on 
Calu-3 cell monolayer. One-way analysis of variance showed 
that the amounts of L deposited in the single preparation and 
in combination preparations (LP1 and LP2) were similar in 
stages 2 and 3. However, significant differences in deposited 
mass were found in stage 4 for L (452.50±32.01 ng) versus 
LP1 (363.96±6.18 ng) and L versus LP2 (235.59±6.05 ng) 
and LP1 (363.96±6.18 ng) versus LP2 (235.59±6.05 ng). This 
could be due to the increased weight/size of the combination 
preparations and the relative distance travelled to stage 4 (illus-
trates lower lung deposition) which could indicate the role of 
impaction rather than sedimentation for larger molecules. 
Figure 2 displays the relative transport rate (P
app
) of 
linezolid measured for L, LP1, and LP2 across the Calu-3 
Transwell in stage 2. Initial transport rates for L, LP1, and 
LP2 were found to be similar at P
app
 values of 1.95×10-4 
(±0.30) ng/mm2/min, 1.93×10-4 (±0.60) ng/mm2/min, and 
1.51×10-4 (±0.96) ng/mm2/min, respectively. In Figure 3, 
L and LP1 presented similar initial P
app
 values of 1.64×10-4 
(±0.61) ng/mm2/min and 1.67×10-4 (±0.01) ng/mm2/min 
in stage 3 again; whereas LP2 displayed a significantly 
lower (P#0.05) P
app
 value of 5.9×10-6 (±0.60) ng/mm2/min. 
Stage 4 represented in Figure 4 shows similar initial trans-
port rates for L, LP1, and LP2 at P
app
 values of 2.20×10-4 
(±0.18) ng/mm/min, 2.02×10-4 (±0.41) ng/mm2/min, 
and 1.96×10-4 (±0.85) ng/mm2/min, respectively. These 
transport rates were also similar to those found in stage 2 
(Figure 2). 
Analysis of the transport after 4 hours showed that 
74.77%±9.50% mass percentage of linezolid from the single 
preparation (L) was detected in the basal chamber for stage 2. 
Figure 1 Total drug masses deposited on calu-3 cell monolayer for , stage 2; , stage 3; and , stage 4. 
Notes: n=2, mean ± standard deviation; one-way analysis of variance, Tukey’s posttest ***P#0.0001. Prep 1 (synsurf + linezolid); prep 2 (synsurf + 2% cholesterol + linezolid).
Abbreviations: l, linezolid; lP1, linezolid + prep 1; lP2, linezolid + prep 2.
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Figure 2 The relative transport rate (Papp) measured for l, lP1, and lP2 across the 
calu-3 Transwell in stage 2. 
Notes: One-way analysis of variance, Tukey’s posttest P#0.05, no significance 
observed. Prep 1 (synsurf + linezolid); prep 2 (synsurf + 2% cholesterol + linezolid).
Abbreviations: l, linezolid; lP1, linezolid + prep 1; lP2, linezolid + prep 2.
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Figure 3 The relative transport rate (Papp) measured for l, lP1, and lP2 across the 
calu-3 Transwell in stage 3. 
Notes: One-way analysis of variance, Tukey’s posttest *P#0.05. Prep 1 (synsurf + 
linezolid); prep 2 (synsurf + 2% cholesterol + linezolid).
Abbreviations: l, linezolid; lP1, linezolid + prep 1; lP2, linezolid + prep 2.
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The percentage of linezolid detected in the basal chamber 
from the combination preparation LP1 (92.22%±0.25%) 
was significantly higher than from the combination prepara-
tion LP2 (56.42%±10.28%) for stage 2 (Figure 5). Stage 3 
(Figure 6) showed very similar mass percentage after trans-
port of linezolid at 4 hours in the basal chamber for the single 
preparation L (86.50%±9.75%) and the combination prepara-
tions LP1 (72.55%±7.92%) and LP2 (88.31%±1.32%). The 
mass percentage of linezolid detected in the basal chamber for 
stage 4 (Figure 7) after 4 hours showed significant difference 
between the combination preparations LP1 (90.79%±0.55%) 
and LP2 (71.27%±12.98%); however, no difference was seen 
for the single preparation L (84.05%±3.44%). 
As seen in Figure 5, analysis of the epithelial cell contents 
revealed that after 4 hours, 18.35%±11.75% of linezolid 
from the single preparation (L), 5.00%±1.36% from the 
combination preparation LP1, and a significant increased 
amount of 35.75%±6.27% from the combination preparation 
LP2 were found in the epithelial cells at stage 2. Therefore, 
at the end of the experiment, 7.84%±0.08% of linezolid 
from L, 2.46%±0.97% from the combination preparation 
LP1, and 7.16%±2.4% from the combination preparation 
LP2 remained on the surface of the epithelial cells. The 
amount of linezolid that remained on the surface of the 
epithelial cells from LP2 significantly increased (P#0.05) 
to that of LP1. The mass percentage remaining of linezolid 
in the single preparation L was also found to be statistically 
more than that of LP1 (Figure 5). 
The mass percentage of linezolid remaining in the epi-
thelial cell contents after 4 hours for stage 3 can be seen in 
Figure 6. Linezolid from LP1 (27.34%±10.19%) was signifi-
cantly higher than that of linezolid from L (8.31%±4.79%) 
and LP2 (9.72%±0.24%), respectively. A similar mass 
percentage of linezolid remaining on the cell surface of the 
apical compartment was detected in stages 3 and 4 for all 
three preparations. The epithelial cell content of linezolid 
for the single preparation L was similar to stages 2 and 3 at 
13.89±1.63 mass percentage at stage 4. The mass percentage 
(stage 4) of linezolid remaining in the epithelial cell contents 
from the combination preparation LP2 (22.22%±8.37%) 
was found to be statistically higher than that of linezolid 
from combination preparation LP1 (8.28%±0.27%). Stage 4 
(Figure 7) showed a similar pattern in the differences of 
Figure 4 The relative transport rate (Papp) measured for l, lP1, and lP2 across the 
calu-3 Transwell in stage 4. 
Notes: One-way analysis of variance, Tukey’s posttest P#0.05, no significance 
observed. Prep 1 (synsurf + linezolid); prep 2 (synsurf + 2% cholesterol + linezolid).
Abbreviations: l, linezolid; lP1, linezolid + prep 1; lP2, linezolid + prep 2.
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Figure 5 Mass percentage of total drug particles in the basal chamber, remaining on the cell surface, and inside the cells after 4 hours after deposition of l, lP1, and lP2 
at stage 2. 
Notes: n=2, mean ± standard deviation (sD); n=3, mean ± sD; one-way analysis of variance, Tukey’s posttests, *P#0.05, **P#0.01. , % in the basal compartment at 240 min; 
, % on cells at 240 min; , % in cells at 240 min. Prep 1 (synsurf + linezolid); prep 2 (synsurf + 2% cholesterol + linezolid).
Abbreviations: l, linezolid; lP1, linezolid + prep 1; lP2, linezolid + prep 2.
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mass percentage for drug remaining within epithelial cell 
lysate contents for LP1 versus LP2 (P#0.05). This direct 
comparison indicates the effect of drug combination type on 
cellular uptake and transport.
surface activity of synsurf preparations
Table 1 summarizes the reduction in surface tension of the dif-
ferent Synsurf preparations. Both prep 1 and prep 2 reduced the 
minimum surface tension to a mean of 49.30±0.82 mN/m and 
50.84±1.15 mN/m, respectively, with no significant differences 
between the two groups. Statistical differences in surface 
tension were found for Synsurf (mean 45.61±1.83 mN/m) 
versus prep 1 (mean 49.30±0.82 mN/m, P,0.0001) and 
prep 2 (mean 50.84±1.15 mN/m, P,0.0001), as well as 
between Synsurf + cholesterol (mean 47.18±0.66 mN/m) 
versus prep 2 (mean 50.84±1.15 mN/m, P,0.0001). Experi-
mental results conducted with the preparations in the pulsat-
ing drop configuration with increasing frequencies (Table 1) 
Figure 6 Mass percentage of total drug particles in the basal chamber, remaining on the cell surface, and inside the cells after 4 hours after deposition of l, lP1, and lP2 
at stage 3. 
Notes: n=2, mean ± standard deviation (sD); n=3, mean ± sD; one-way analysis of variance, Tukey’s posttests, *P#0.05. , % in the basal compartment at 240 min; , % on 
cells at 240 min; , % in cells at 240 min. Prep 1 (synsurf + linezolid); prep 2 (synsurf + 2% cholesterol + linezolid).
Abbreviations: l, linezolid; lP1, linezolid + prep 1; lP2, linezolid + prep 2.
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Figure 7 Mass percentage of total drug particles in the basal chamber, remaining on the cell surface, and inside the cells after 4 hours after deposition of l, lP1, and lP2 
at stage 4. 
Notes: n=2, mean ± standard deviation (sD); n=3, mean ± sD; one-way analysis of variance, Tukey’s posttests, *P#0.05. , % in the basal compartment at 240 min; , % on 
cells at 240 min; , % in cells at 240 min. Prep 1 (synsurf + linezolid); prep 2 (synsurf + 2% cholesterol + linezolid).
Abbreviations: l, linezolid; lP1, linezolid + prep 1; lP2, linezolid + prep 2.
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showed no statistical differences between the different prepa-
rations for the complex surface dilatational modulus as well 
as for the elastic modulus. As could be expected, addition 
of cholesterol to Synsurf increased the viscous modulus 
significantly (mean 14.03±3.08 mN/m to 20.63±1.97 mN/m, 
P,0.0001). However, addition of linezolid to Synsurf con-
taining cholesterol in order to compose prep 1 decreased the 
viscous modulus significantly again to a mean surface tension 
of 10.14±1.6 mN/m, P,0.0001. Statistical difference in the 
viscous modulus between prep 1 and prep 2 was also found 
significant with a P-value ,0.05.
surface morphology of calu-3 cells 
grown via ali culture
SEM was used to study the surface of the cells after 11 days 
in ALI culture (Figure 8), the point at which the TEER 
maintained its maximum resistance of ~750–1,000 Ω cm2 
and the cell layer was presumed to be “intact” with fully 
formed tight junction proteins accompanied with mucus 
production. The boundaries between the cells were also 
observed as clearly shown.
Calu-3 cells were clearly shown to express cilia after 
7 days in culture (Figure 9A and B); a characteristic trait 
that is only present in a differentiated pseudostratified epi-
thelium. Around 95% of all cells in each sample displayed 
cilia; however, some cell populations displayed a diverse 
degree of differentiation. The shape and length of cilia also 
varied between cells, and some displayed a “clumping” 
characteristic which has also been described by Proctor18 
who reasoned it to be due to the fixing method. 
Figure 10 displays highly magnified images visualizing 
the particles present on the cell surface post-pMDI fire. Par-
ticle size delivered by the pMDI was formulation dependent. 
The particles have been determined by SEM visualization and 
indicated that, in general, the particles were well dispersed in 
60 seconds post-fire. LP1 displayed a more striated dispersion 
(Figure 11A and B), whereas agglomerates were preferen-
tially seen for LP2 (Figure 11C). Images are representative 
of n=2 independent experiments.
Discussion
In this study, we compared the diffusion kinetics of linezolid 
formulated alone and within two preparations of a synthetic 
surfactant Synsurf-based pMDI (LP1 and LP2) across a 
Calu-3 cell Transwell culture. The different surfactant drug 
combinations allow for an evaluation of the significance of 
the experimental model system, as well as assessment of the 
formulations providing a possible noninvasive, site-specific, 
delivery model via pMDI. From a drug delivery perspective, 
this is valuable in the development and characterization of a 
drug-loaded synthetic surfactant. In this regard, this may lead 
Table 1 surface tension and interface rheology activity of synsurf® 
preparations containing 90 µg of the pulmonary surfactant with 
or without cholesterol (2 weight%) and/or linezolid (90 µg) in 
100 mM nacl solution
Pendant drop, mN/m
Surface 
tension
Synsurf Synsurf + 
cholesterol
Synsurf 
prep 1
Synsurf 
prep 2
Mean 45.61±1.826 47.18±0.6597 49.30±0.82 50.84±1.15
Minimum 43.82 46.24 48.27 49.01
Maximum 48.55 47.90 50.46 52.02
Pulsating drop, mN/m
Viscoelastic 
properties
complex surface dilational modulus
Mean 68.49±11.66 67.13±12.19 56.95±10.68 61.62±9.47
Minimum 44.41 44.67 34.49 42.36
Maximum 76.72 77.43 64.82 68.83
elastic modulus
Mean 66.87±12.29 63.64±13.34 55.97±10.96 59.91±3.61
Minimum 42.36 39.73 33.29 39.71
Maximum 75.84 74.93 64.25 67.68
Viscous modulus
Mean 14.03±3.08 20.63±1.97 10.14±1.60 13.71±2.56
Minimum 10.97 17.88 8.489 10.76
Maximum 19.00 23.64 12.51 17.55
Notes: Prep 1 (synsurf + linezolid); prep 2 (synsurf + 2% cholesterol + linezolid). 
Preparations were analyzed using pendant and pulsating drop configurations with 
a One attension Theta Optical Tensiometer. Data expressed as mean ± standard 
deviation. Bolded mN/m pendant drop and viscous modulus values reflect significant 
ratios.
Figure 8 (A) linezolid particles deposited on top of the cells for stage 2; 
(B) examples of tight junction belt fractures after freeze-drying for scanning electron 
microscopy. 
Note: scale bar =5 µm, original magnification 7,000×, WD (working distance) =8.0 
mm, acc, accelerating voltage (beam energy) =5.0 kV.
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to the better understanding of the clinical relevance achieved 
by concomitant use of surfactant-drug formulations in the 
treatment of pulmonary tuberculosis.
Under our experimental conditions with a total dose of 
500 µg (C
0
), fired from the pMDI, the concentration delivered 
was calculated in different regions of the lung.16 The same 
reasoning could be used for the deposition of the compound 
at the different stages of the NGI. In the large conducting 
airways (stage 1 of the NGI), the possible deposited con-
centration could amount from 30 to 300 ng/cm2. The peak 
concentration in the segmental bronchi (stage 2) and the small 
conducting airways (stage 3) could be 30 ng/cm2, and in the 
alveoli, the concentration was shown to be 0.1–1 ng/cm2 
(stage 4–5), which correlated with the total mass deposited 
on the Calu-3 cell surface (Figure 1). 
In studies conducted with Caco-2 cells, it was shown that 
the apparent permeability coefficients of compounds with 
different physicochemical properties and mechanisms of per-
meation have a very distinctive effect on the rate of transport. 
Moreover, drug permeability under Fick’s law (Equation 1) 
assumes that the driving force is a concentration gradient 
difference between the single barrier of the cell monolayer 
that leads to either the sequestration of lipophilic drugs into 
the phospholipid membranes in transcellular diffusion or the 
partitioning of hydrophilic drugs into aqueous tight-junctional 
areas in paracellular diffusion.19,20 On the other hand, high 
passive permeability is not necessarily synonymous with 
high lipophilicity because hydrogen bonding or the presence 
of an unstirred water layer for a group of compounds can 
delimit permeability to such an extent that the compounds 
would exhibit a low permeability.21 This theory may be the 
explanation for the decreased permeability of linezolid in 
LP2 containing cholesterol for stage 2 and 3 compared with 
that of L and LP1. The addition of 2 wt% cholesterol to 
Synsurf prep 2 may have contributed to the more lipophilic 
nature of the compound LP2 as a whole; however, our data 
show that LP2 displayed the lowest P
app
 value, albeit not all 
significant, of all three compounds over all the three stages 
of the NGI (Figures 2–4). These findings differ from that 
of a report by Foster et al which found a linear relationship 
Figure 9 scanning electron microscopy images of calu-3 epithelial layers grown at air–liquid interface where cilia on the surface as well as a mucosal layer is visible. 
Notes: (A) cilia at 30,000× and (B) 50,000× display varied sizes and shapes. (A) scale bar =1 µm, original magnification 30,000×, working distance (WD) =8.0 mm, acc, 
accelerating voltage (beam energy) =4.0 kV. (B) scale bar =500 nm, PROBE 7, original magnification 50,000×, WD =8.0 mm, acc =5.0 kV.
Figure 10 scanning electron microscopy images visualizing the deposition of synsurf® and linezolid on the calu-3 epithelial layers grown at air–liquid interface immediately 
post-pMDI-fire. 
Notes: (A) linezolid + prep 1 (lP1) particles were found to be well dispersed and measured between 500 nm and 1 µm; (B) lP1 particle displaying a “burst” characteristic, 
spreading onto the mucosal layer; (C) linezolid + prep 2 (lP2) particle displayed a distinctive “comet-like” tail appearance. The particle measured 500 nm in diameter. 
(A) scale bar =1 µm, original magnification 30,000×, working distance (WD) =8.0 mm, accelerating voltage (beam energy) (acc) =5.0 kV. (B) scale bar =1 µm, PrOBe 7, 
original magnification 35,000×, WD =8.0 mm, acc =4.0 kV. (C) scale bar =500 nm, PROBE 7, original magnification 50,000×, WD =8.0 mm, acc =5.0 kV. Prep 1 (synsurf + 
linezolid); prep 2 (synsurf + 2% cholesterol + linezolid).
Abbreviation: pMDi, pressurised metered dose inhaler.
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between the log P
app
 and the log octanol/water partition coef-
ficient.22 The moderate lipophilicity of linezolid is shown in 
Figures 5–7 where the remaining concentration values are 
conveyed for all three pMDI preparations over all the three 
stages. Linezolid displays the highest concentration for 
remaining drug on the surface of the Calu-3 monolayer at 
stages 2 and 3 compared with that of linezolid in combina-
tion with either of the Synsurf preparations (LP1 and LP2). 
One can thus speculate that linezolid alone and LP2 have the 
ability to embed within the cell as their lysate concentration 
values are thus similar. In such a situation, electrostatic and 
hydrophobic interactions are enhanced and may reinforce 
each other. The different particle sizes among the stages 
are also to be taken into consideration when deliberating 
the remaining surface drug of cell lysate concentrations; as 
there could very well be a higher concentration of drug in a 
certain particle size distribution and thus more deposited on 
a certain stage than others. 
Synthetic particles of diverse forms have gained increas-
ing attention, as evident from recent studies, which suggested 
that morphology could influence the mechanisms of drug 
delivery in many ways.23–27 In studies conducted by Lu et al, 
it was shown that key parameters such as surfactant changing 
concentration can alter viscoelasticity and surface tension of 
the solution that will change the morphology of the prepa-
ration such as filament forming between drops. Instead of 
filaments breaking rapidly, they change from a spherical to 
a spindle-like appearance.28 Under our experimental condi-
tions, we found a more agglomerated and “ribbon-like” 
nature of LP2 (Figure 11C) compared to that of cholesterol-
devoid LP1 (Figure 11B) that displayed more perpendicular 
spreading like characteristics. Moreover, the temperature at 
which DPPC transitions from the gel phase to the rippled 
phase (Tp =36°C) could also be of significance where 
DPPC-based liposomes form vesicle pearling filaments 
as seen in Figure 11A and B.28,29 This is reflected for both 
Synsurf/linezolid preparations that displayed similar supra-
molecular entanglements with the incorporation of droplets 
and beaded filaments. 
The delivered particles and drug dose showed a high 
dependency from the preparation that was aerosolized. The 
Synsurf/linezolid preparations (LP1 and LP2) showed that 
an assortment of particle ranges from 500 nm to 2 µm in the 
emitted dose which have been similarly reported by Zanen 
et al and other studies.30–32 It is generally accepted that to be 
therapeutically effective, the particles should be in the range 
of 1–5 µm since particles .5 µm will generally impact in the 
oropharynx and be swallowed, whereas those ,1 µm may 
remain entrained in the airstream and be exhaled during the 
next breathing cycle.16 The smaller particles may be deposited 
peripherally and may be more effective since surfactant is 
present and functions in the alveolar region. The diameters 
of LP1 and LP2 pMDI particles measured with SEM imaging 
revealed suitable size distribution to achieve desired lung 
distribution and still be deemed therapeutically effective. 
However, fast inhalations (.60 L/min) such as that illustrated 
with a pMDI result in a reduced peripheral deposition because 
the aerosol is more readily deposited by inertial impaction in 
the conducting airway and oropharyngeal regions.33 
It is known that the composition of pulmonary surfac-
tant influences its biophysical properties. Synsurf consists 
of a mixture of DPPC (saturated lipid) combined with 10% 
phosphatidylglycerol (contains unsaturated fatty acids) and 
the nonionic detergent tyloxapol as well as 1-hexadecanol 
as a spreading agent.11 In addition to the above compounds, 
prep 1 contained linezolid and prep contained 2% by weight 
cholesterol (neutral lipid) and linezolid. In natural human 
pulmonary surfactant, cholesterol is present between 5% and 
Figure 11 scanning electron microscopy images visualizing the deposition of synsurf® on the calu-3 epithelial layers grown at air–liquid interface. 
Notes: Unique spreading properties over the mucosal layers are visible 60 seconds post-pMDI-fire for (A and B) lP1 which displays a striated dispersion, whereas 
(C) lP2 displays a more agglomerated ribbon-like appearance. (A) scale bar =5 µm, PROBE 7, original magnification 4,000×, working distance (WD) =8.0 mm, accelerating 
voltage (beam energy) (acc) =5.0 kV. (B) scale bar =1 µm, original magnification 20,000×, WD =8.0 mm, acc =5.0 kV. (C) scale bar =2 µm, PROBE 7, original magnification 
12,000×, WD =8.0 mm, acc =5.0 kV. Prep 1 (synsurf + linezolid); prep 2 (synsurf + 2% cholesterol + linezolid).
Abbreviations: l, linezolid; lP1, linezolid + prep 1; lP2, linezolid + prep 2; pMDi, pressurised metered dose inhaler.
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10% weight of the lipid components with no inhibitory 
effect on surface tension as seen with supra-physiological 
concentrations in adult respiratory distress syndrome.34 
Moreover, one of the most important functions of pulmonary 
surfactant is increasing the surface pressure upon exhala-
tion. Although $8% by weight cholesterol interferes with 
functionality in reconstituted pulmonary surfactants films,35 
we found that during compression–expansion experiments, 
a maximum and minimum surface pressure of ~69 mN/m 
and ~2 mN/m, respectively, could be reached for prep 1 and 
prep 2 (results not shown). In view of our results, we are of the 
opinion that Synsurf as a replacement pulmonary surfactant 
not only seems to be able to cope with cholesterol inhibition 
but that both prep 1 and prep 2 are beneficial test combina-
tions for use during aerosolization of linezolid.
Conclusion
In summary, a synthetic surfactant Synsurf-based pMDI was 
investigated to deliver the antibiotic, linezolid. Although the 
small sample size with a post hoc power of analysis may be 
seen as a limitation, we addressed this by using CIs to estimate 
the magnitude of effects via a Tukey post hoc test.36 Finally, 
our data show that linezolid can be aerosolized in desired par-
ticle ranges for optimal lung deposition. The use of the NGI 
and the Calu-3 cell line for the assessment of linezolid dis-
solution and transport after particle codeposition has allowed 
for a more realistic investigation with respect to the in vivo 
situation. This paper is the first to study Synsurf in a pMDI 
in the evolution of surfactant therapy and drug delivery. 
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